

January 17, 2018

BSE Limited
Floor 25, P. J. Towers
Dalal Street, Fort
Mumbai - 400 001

The National Stock Exchange of India Limited
Exchange Plaza
Bandra Kurla Complex
Bandra (E), Mumbai - 400 051

Dear Sirs,

Re.: Changes in the Board of Directors

Pursuant to the provisions of Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform about the following changes in the Board of Directors of the Company:


1. **Resignation of Mr. Pramod Yadav:** Consequent to his appointment as CEO Designate of Jubilant Pharma Limited, a wholly owned subsidiary of the Company, Mr Pramod Yadav has submitted his resignation as Director and Whole-time Director of the Company. The Board has, at its meeting held today i.e. January 17, 2018, accepted his resignation with immediate effect.
2. **Appointment of Mr. Rajesh Srivastava as Whole-time Director:** The Board has, at the said meeting, approved the appointment of Mr. Rajesh Srivastava as an Additional Director and Whole-time Director of the Company with immediate effect. Brief profile of Mr. Srivastava is given as an Annexure to this letter. Mr. Srivastava is not related to any Director of the Company.

Changes in the Key Managerial Personnel are enclosed.

We request you to take the same on record.

Thanking you,

Yours faithfully,
For Jubilant Life Sciences Limited



Rajiv Shah
Company Secretary

Encl.: As above

A Jubilant Bhartia Company

OUR VALUES



Jubilant Life Sciences Limited
1-A, Sector 16-A,
Noida-201 301, UP, India
Tel: +91 120 4361000
Fax: +91 120 4234895-96
www.jubl.com

Regd Office:
Bhartiagram, Gajraula
Distt. Amroha - 244 223,
UP, India
CIN : L24116UP1978PLC004624



Annexure

Mr. Rajesh Srivastava

Rajesh Srivastava, 52 years, presently the Co-CEO of Jubilant Life Science Ingredients business of Jubilant Life Sciences. Rajesh holds B. Tech degree in Chemicals Technology from Harcourt Butler Technological University (HBTU) Kanpur and Master in Marketing Management from Jamunalal Bajaj Institute of Management Studies, Mumbai.

Rajesh has over 30 years of professional experience and has been with Jubilant for more than 17 Years. Prior to this, Mr. Srivastava has held leadership position at Ranbaxy in their Fine Chemicals Business, P&L responsibility for Coating & Petroleum business unit of Indofil Chemicals Company and was Regional Head of Sales with Shalimar Paints.

Change in Key Management Personnel of Jubilant Life Sciences Limited

Noida (UP), India, Tuesday, January 17, 2018

Jubilant Life Sciences Limited ('JLL'), an integrated Pharmaceuticals and Life Sciences Company informed that **Mr. Pramod Yadav is appointed as Chief Executive Officer Designate of Jubilant Pharma Limited, Singapore ('JPL')**, a wholly-owned material subsidiary of JLL.

Mr. Gurpartap Singh Sachdeva (Mr. GP Singh) has resigned from the CEO position of JPL effective from March 31, 2018 due to his personal reasons. Mr. Yadav would assume the role and responsibilities as CEO of JPL with effect from April 1, 2018. Mr. Yadav will have overall responsibility for the operations of JPL and will report to the Jubilant Pharma Limited Board. He will be based at the JPL Head Quarters at Yardley, PA, USA.

Mr. Yadav presently, is the Co-CEO of Life Science Ingredients business of JLL. He holds a Bachelor's degree in Technology from UDCT (University Department of Chemical Technology, Mumbai) and a Masters in Marketing Management from Jamnalal Bajaj Institute of Management Studies, Mumbai, India. He brings in 3 decades of experience of managing various businesses at global scale and has been with Jubilant for more than 22 years.

Consequent to his appointment as CEO Designate of Jubilant Pharma Limited, Mr. Yadav has submitted his resignation as Director and Whole-time Director of JLL effective from January 17, 2018. The Board has, at its meeting held today i.e. January 17, 2018, accepted his resignation with immediate effect.

The Board of Directors of the company, at the said meeting, has appointed, **Mr. Rajesh Srivastava as CEO of Life Science Ingredients Business (LSI)** to take the overall responsibility of the operations of LSI Business. Also Mr. Srivastava has been appointed as an Additional Director and Whole-time Director of JLL at the said meeting with immediate effect.

Mr. Srivastava is presently, the Co-CEO of the Life Science Ingredients business of JLL. He holds B.Tech degree in Chemicals Technology from Harcourt Butler Technological University (HBTU) Kanpur and Master in Marketing Management from Jamnalal Bajaj Institute of Management Studies, Mumbai. Rajesh has over 30 years of professional experience and has been with Jubilant for more than 17 Years.



About Jubilant Life Sciences

Jubilant Life Sciences Limited is an integrated global pharmaceutical and life sciences company engaged in Pharmaceuticals, Life Science Ingredients and Drug Discovery Solutions. The Pharmaceuticals segment, through its wholly owned subsidiary Jubilant Pharma Limited, is engaged in manufacture and supply of APIs, Solid Dosage Formulations, Radiopharmaceuticals, Allergy Therapy Products and Contract Manufacturing of Sterile and Non-sterile products through 6 USFDA approved manufacturing facilities in India, USA and Canada and a network of over 50 radiopharmacies in the US. The Life Science Ingredients segment, is engaged in Specialty Intermediates, Nutritional Products and Life Science Chemicals through 5 manufacturing facilities in India. The Drug Discovery Solutions segment, provides proprietary in-house innovation & collaborative research and partnership for out-licensing through 3 world class research centres in India and USA. Jubilant Life Sciences Limited has a team of around 7,600 multicultural people across the globe and is committed to deliver value to its customers across over 100 countries. The Company is well recognized as a 'Partner of Choice' by leading pharmaceuticals and life sciences companies globally. For more info: www.jubl.com.